---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-043555"
form_type: "8-K/A"
ticker: "DTIL"
cik: "0001357874"
company_name: "PRECISION BIOSCIENCES INC"
filed_at: "2023-08-21T23:59:59+00:00"
generated_at: "2026-06-11T06:03:38.979451+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Precision BioSells CAR T manufacturing to Imugene for $8M cash and $13M convertible notes

## Summary
- Imugene acquired CAR T manufacturing infrastructure, including MCAT facility, for $8M cash and $13M in 1-year non-interest-bearing convertible notes.
- Pro forma net loss for H1 2023 reduced from $37M to $22M, reflecting discontinued CAR T operations.
- Precision granted Imugene exclusive license to develop/commercialize azer-cel and up to three additional CAR T candidates.
- Pro forma balance sheet shows $146M cash; convertible note receivable of $12M at estimated fair value.
- Transaction results in estimated $10M gain recorded in discontinued operations.

## SEC filing metadata
- accession: 0000950170-23-043555
- form_type: 8-K/A
- ticker: DTIL
- cik: 0001357874
- company_name: PRECISION BIOSCIENCES INC
- filed_at: 2023-08-21T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1357874/000095017023043555/0000950170-23-043555-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1357874/000095017023043555/dtil-20230815.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-043555
- JSON: https://secwatch.observer/filing/0000950170-23-043555.json
- Plain text: https://secwatch.observer/filing/0000950170-23-043555.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.